In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist

Drugs in R and D

Volumn 7, Issue 4, 2006, Pages 219-231

  Corcóstegui, Reyes ^a   Labeaga, Luis ^a   Innerárity, Ana ^a   Berisa, Agustín ^a   Orjales, Aurelio ^a,b  

^a FAES SA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; BILASTINE; BRADYKININ; CETIRIZINE; DEXAMETHASONE; FEXOFENADINE; HISTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; OXAZOLONE; SEROTONIN; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHUS PHENOMENON; ARTICLE; BRONCHOSPASM; CAPILLARY PERMEABILITY; CONTACT DERMATITIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG STRUCTURE; EAR; EXTRAVASATION; GUINEA PIG; IN VIVO STUDY; LETHALITY; MALE; MEDICAL ASSESSMENT; MICROVASCULARIZATION; MOUSE; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PRIORITY JOURNAL; RAT; SKIN EDEMA; TRACHEA;

ANIMALS; BENZIMIDAZOLES; BRADYKININ; BRONCHIAL SPASM; CAPILLARY PERMEABILITY; CETIRIZINE; DERMATITIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HISTAMINE; HISTAMINE ANTAGONISTS; HYPERSENSITIVITY; MALE; MICE; MOLECULAR STRUCTURE; OXAZOLONE; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, HISTAMINE H1; SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP; TERFENADINE; TIME FACTORS;

EID: 33745242491     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200607040-00002     Document Type: Article

References (17)

1. Labeaga L, Corcóstegui R, Innerárity A, et al. Bilastine: a novel potent, selective, and orally effective antihistamine and antiallergic drug: I. In vitro characterization. XXVI Congreso de la Sociedad Española de Farmacología; 2004 Sep 26-29; Salamanca, Spain
2. 1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005; 6: 371-84
3. Corcóstegui R, Labeaga L, Orjales A. Bilastine: a novel, potent, selective, and orally effective antihistamine and antiallergic drug: II. In vivo characterization. XXVI Congreso de la Sociedad Española de Farmacología; 2004 Sep 26-29; Salamanca, Spain
4. Lefebvre R, Salmon J, Leconte J, et al. Influence de l'acide ε- aminocaproique sur l'augmentation de la permeabilité vasculaire chez le rat par l'histamine. CR Soc Biol 1962; 156: 183-6
5. Udaka K, Takeuchi Y, Moval H. Simple method for quantification of enhanced vascular permeability. Proc Soc Exp Biol Med 1970; 133: 1384-7
6. Planquois JM, Mottin G, Artola M, et al. Effects of phosphodiesterase inhibitors and salbutamol on microvascular leakage in guinea pig trachea. Eur J Pharmacol 1998; 344: 59-66
7. Van Wauwe S, Awouters F, Niemegeers CJ, et al. In vivo pharmacology of astemizole, a new type of H1-antihistaminic compound. Arch Int Pharmacodyn Ther 1981; 251: 39-51
8. Abou-Gharbia M, Nielsen ST, Andree TH, et al. Preclinical profile of Wy-49,052, a new H1-antagonist. Drug Dev Res 1990; 21: 63-78
9. Niemegeers CJE, Awouters F, Van Nueten JM, et al. Protection of rats from compound 48/80-induced lethality: a simple test for inhibitors of mast cell-mediated shock. Arch Int Pharmacodyn 1978; 134: 167-76
10. Flancbaum L, Fitzpatrick JC, Fisher H. Effect of histamine receptor antagonists on mortality in compound 48/80-induced shock. Circ Shock 1990; 32: 133-40
11. Konzett H, Rössler R. Versuchsanordnung zu Untersuchungen an der Bronchialmuskulatur. Arch Exp Pathol Pharmacol 1940; 195: 71
12. Mota I. The mechanism of anaphylaxis: I. Production and biological properties of 'mast cell sensitizing' antibody. Immunology 1964; 7: 681-99
13. Hyung-min K, Seong-Hoon C. Lavender oil inhibits immediate-type allergic reaction in mice and rats. J Pharm Pharmacol 1999; 51: 221-6
14. Inagaki N, Miura T, Nagai H, et al. Active cutaneous anaphylaxis (ACA) in the mouse ear. Jpn J Pharmacol 1992; 59: 201-8
15. Omote M, Sakai K, Mizusuawa H. Acute effect of deflazacort and its metabolite 21-desacetyl-deflazacort on allergic reactions. Arzneimittel Forschung 1994; 2: 149-53
16. Evans DP, Hossack M, Thomson DS. Inhibition of contact sensitivity in the mouse by topical application of corticosteroids. Br J Pharmacol 1971; 43: 403-8
17. Van de Hoven WE, Van der Berg TP, Hall DWR, et al. Development of an ear edema model of contact hypersensitivity to avoid false-positive results due to interactions between hapten and test agents. J Pharmacol Toxicol Methods 1977; 38: 53-7